Bleomycin pulmonary toxicity

Bleomycin is really the primary chemotherapy related to toxicity in Hodgkin lymphoma. The ABVD regimen has pulmonary toxicity, which can be

Pulmonary toxicity is the medical name for side effects on the lungs. gemcitabine, bleomycin, mitomycin C, busulfan, cyclophosphamide, chlorambucil

The most common serious adverse effect of bleomycin is pulmonary toxicity, often referred to as bleomycin pulmonary toxicity or BPT. This adverse effect sometimes leads to pulmonary fibrosis, a chronic and irreversible disease with a poor prognosis.

List of references Hay, Mechanisms of bleomycin-induced lung damage, Arch Toxicol, № 65, с. Jules-Elysee, Bleomycin-induced pulmonary toxicity, Clinics Chest

BPT: Bleomycin Pulmonary Toxicity induced renal toxicity on bleomycin-induced pulmonary toxicity in patients with disseminated testicular.

by WA Al-Jizani 2024 Cited by 5ABSTRACT. Background: Bleomycin pulmonary toxicity (BPT) has been described in Hodgkin's lymphoma (HL) patients treated with bleomycin-

One of the fatal side effect of bleomycin is pulmonary toxicity. Here we present three cases of Hodgkin s lymphoma treated with ABVD chemotherapy who had pulmonary toxicity. All three developed bleomycin induced pulmonary toxicity in the form of pulmonary fibrosis during treatment of the disease.

Pulmonary toxicities occur in 10% of treated patients. In approximately 1%, the nonspecific pneumonitis induced by bleomycin progresses to pulmonary fibrosis

The major limitation of bleomycin use is the development of bleomycin induced pulmonary toxicity (BPT). Bleomycin-induced cell injury stimulates an inflammatory response n the lung. G-csf has been shown in animal models to augment this response.